Filing identity and period
Important metadata discrepancy: The supplied filing is Synta Pharmaceuticals Corp.’s unaudited Form 10-Q for the quarter ended September 30, 2012—not a filing for Madrigal Pharmaceuticals, Inc. The summary below reflects the Synta filing.
Synta is a clinical-stage biopharmaceutical company developing oncology and inflammatory-disease drug candidates. It reported no product revenue and stated it expected significant operating losses to continue.
Financial results and liquidity
| Metric | Q3 2012 | Nine months 2012 | Comparable 2011 |
|---|---|---|---|
| Revenue | $0 | $0.147 million | $1.664 million Q3; $4.161 million nine months |
| Research and development | $11.743 million | $35.061 million | $10.751 million Q3; $30.605 million nine months |
| General and administrative | $2.796 million | $8.324 million | $3.131 million Q3; $8.749 million nine months |
| Net loss | $14.996 million | $44.667 million | $12.734 million Q3; $36.637 million nine months |
| Net loss per share | $0.25 | $0.77 | $0.26 Q3; $0.79 nine months |
| Operating cash used | Not separately stated for Q3 | $41.612 million | $36.814 million nine months |
At September 30, cash and cash equivalents were $29.442 million and marketable securities were $25.697 million, totaling approximately $55.1 million. Working capital was approximately $37.0 million. Total assets were $57.613 million and total liabilities $25.423 million. Term loans totaled $14.354 million; the GECC loan carried 9.75% interest and the Oxford loan 13.35%. No product sales means product gross margin is not applicable.
Financing activities provided $57.442 million in the first nine months, including approximately $33.0 million net from a public offering and $25.8 million net from a July registered direct offering to directors, including the largest stockholder. The company had sold no shares under its $35 million at-the-market agreement as of the filing. Common shares outstanding rose to 61.881 million from 49.540 million at year-end 2011.
Changes versus the prior period
- Nine-month revenue fell 98% to $0.147 million, mainly because Roche collaboration revenue ended after Roche terminated the agreement effective February 16, 2012; the DoD grant also concluded in March 2012.
- Nine-month R&D increased 15% to $35.061 million, chiefly from higher ganetespib trial and development costs. Ganetespib R&D was $31.7 million versus $21.7 million in the prior-year period.
- Nine-month net loss increased by $8.030 million. Quarterly loss per share was lower than in Q3 2011, but the weighted-average share count increased materially.
- Cash and marketable securities increased approximately $15.4 million from December 31, 2011, principally due to equity offerings; operating cash use increased year over year.
Outlook, developments, and risks
- Management estimated existing cash resources would fund operations into the second half of 2013, based on then-current operating plans. It cautioned that trial plans and funding needs could change and that additional capital might be needed sooner.
- Management expected higher 2012 ganetespib spending as it advanced GALAXY and conducted CHIARA and ENCHANT. It expected lower spending on CRACM and elesclomol than in 2011. No formal earnings or revenue guidance was provided.
- In interim GALAXY results for 172 adenocarcinoma patients, median overall survival was 7.4 months with docetaxel alone and had not been reached with ganetespib plus docetaxel. Progression-free survival was 2.8 versus 4.2 months and response rates were 8% versus 16%. These were interim results; the filing reports one-sided p-values of 0.076 for progression-free survival and 0.078 for response rate, so the findings were not definitive.
- Management reported stronger survival signals in certain subgroups and said those results informed a planned Phase 3 design. The Phase 3 trial was expected to enroll about 500 patients; management anticipated Phase 2b follow-up data in 2013 and Phase 3 overall-survival analyses in 2014. These are forward-looking expectations, not guarantees.
- Enrollment of non-adenocarcinoma patients in GALAXY was stopped after lack of observed benefit, possible safety concerns including bleeding risk, and a trend toward worse survival. In the adenocarcinoma analysis, grade 3 or 4 adverse events were reported in 56% of combination-arm patients versus 37% of controls; diarrhea was more common with the combination.
- Roche termination returned rights to the CRACM compounds to Synta, but potential future product sales could carry a low-single-digit royalty to Roche. The company reported no material legal proceedings and no material changes to its previously disclosed risk factors.
- Key risks include clinical-trial efficacy and safety, regulatory approval, continued cash burn, dependence on external financing or partnerships, possible dilution or loss of product rights, and debt covenants and repayment obligations.
Most important facts to verify
- Confirm the issuer: the source is Synta Pharmaceuticals Corp., despite the request identifying Madrigal Pharmaceuticals.
- Verify current cash runway against actual subsequent spending, financing, and trial costs; the filing’s estimate extended only into the second half of 2013.
- Review final GALAXY results and the Phase 3 protocol, including subgroup selection, statistical significance, and safety findings; interim data are not proof of efficacy.
- Check subsequent equity issuance, dilution, debt repayments, and compliance with loan covenants.
- Confirm the status and commercial rights of ganetespib, elesclomol, and the returned Roche CRACM compounds, including any royalty obligations.